A phase II, non-randomized, multi-center study to evaluate the efficacy and safety of pazopanib (GW786034) in subjects with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 18 Jan 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Jun 2009 Actual end date (1 Apr 2009) added as reported by ClinicalTrials.gov.
- 24 Jun 2009 Actual patient number (14) added as reported by ClinicalTrials.gov.